Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia
Abstract Quizartinib prolongs QT interval through inhibition of the slow delayed rectifier potassium current (IKs). We used non‐linear mixed‐effects modeling to explore the relationship between quizartinib and its pharmacologically active metabolite AC886 and the Fridericia‐corrected QT interval (QT...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.70065 |